Improved General and Height-Specific Quality of Life in Children With Short Stature After 1 Year on Growth Hormone.

Autor:	González Briceño LG; Pediatric Endocrinology, Diabetology and Gynecology Department, Hôpital Universitaire Necker-Enfants Malades [Assistance Publique Hôpitaux de Paris (AP-HP)], Paris, France.; European Society for Paediatric Endocrinology (ESPE) Clinical Fellowship, Paris, France., Viaud M; Pediatric Endocrinology, Diabetology and Gynecology Department, Hôpital Universitaire Necker-Enfants Malades [Assistance Publique Hôpitaux de Paris (AP-HP)], Paris, France.; Centre de référence des maladies endocriniennes rares de la croissance et du développement, Paris, France., Beltrand J; Pediatric Endocrinology, Diabetology and Gynecology Department, Hôpital Universitaire Necker-Enfants Malades [Assistance Publique Hôpitaux de Paris (AP-HP)], Paris, France.; Centre de référence des maladies endocriniennes rares de la croissance et du développement, Paris, France.; Université Paris Descartes, Paris, France., Flechtner I; Pediatric Endocrinology, Diabetology and Gynecology Department, Hôpital Universitaire Necker-Enfants Malades [Assistance Publique Hôpitaux de Paris (AP-HP)], Paris, France.; Centre de référence des maladies endocriniennes rares de la croissance et du développement, Paris, France., Dassa Y; Pediatric Endocrinology, Diabetology and Gynecology Department, Hôpital Universitaire Necker-Enfants Malades [Assistance Publique Hôpitaux de Paris (AP-HP)], Paris, France.; Centre de référence des maladies endocriniennes rares de la croissance et du développement, Paris, France., Samara-Boustani D; Pediatric Endocrinology, Diabetology and Gynecology Department, Hôpital Universitaire Necker-Enfants Malades [Assistance Publique Hôpitaux de Paris (AP-HP)], Paris, France.; Centre de référence des maladies endocriniennes rares de la croissance et du développement, Paris, France., Thalassinos C; Pediatric Endocrinology, Diabetology and Gynecology Department, Hôpital Universitaire Necker-Enfants Malades [Assistance Publique Hôpitaux de Paris (AP-HP)], Paris, France.; Centre de référence des maladies endocriniennes rares de la croissance et du développement, Paris, France., Pauwels C; Pediatric Endocrinology, Diabetology and Gynecology Department, Hôpital Universitaire Necker-Enfants Malades [Assistance Publique Hôpitaux de Paris (AP-HP)], Paris, France.; Centre de référence des maladies endocriniennes rares de la croissance et du développement, Paris, France., Busiah K; Pediatric Endocrinology, Diabetology and Obesity, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., Pinto G; Pediatric Endocrinology, Diabetology and Gynecology Department, Hôpital Universitaire Necker-Enfants Malades [Assistance Publique Hôpitaux de Paris (AP-HP)], Paris, France.; Centre de référence des maladies endocriniennes rares de la croissance et du développement, Paris, France., Jaquet D; Pediatric Endocrinology, Diabetology and Gynecology Department, Hôpital Universitaire Necker-Enfants Malades [Assistance Publique Hôpitaux de Paris (AP-HP)], Paris, France., Polak M; Pediatric Endocrinology, Diabetology and Gynecology Department, Hôpital Universitaire Necker-Enfants Malades [Assistance Publique Hôpitaux de Paris (AP-HP)], Paris, France.; Centre de référence des maladies endocriniennes rares de la croissance et du développement, Paris, France.; Université Paris Descartes, Paris, France.; l'Institut des Maladies Génétiques (IMAGINE Institute), Paris, France.
Jazyk:	angličtina
Zdroj:	The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2019 Jun 01; Vol. 104 (6), pp. 2103-2111.
DOI:	10.1210/jc.2018-02523
Abstrakt:	Objective: Short stature in children and adolescents may lead to social and emotional stress, with negative effects on quality of life (QoL). GH treatment may improve QoL through height normalization. Our objective here was to evaluate general and height-specific QoL after 1 year of GH treatment. Design: Prospective, single-center, observational cohort study. Methods: Children ≥ 4 years of age starting GH at our center from 2012 to 2015 to treat short stature were studied. Patients with serious diseases, syndromic short stature, or developmental delay were excluded. At treatment initiation and 1 year later, patients and their parents completed the general PedsQL 4.0 and height-specific Quality of Life in Short Stature Youth (QoLiSSY) questionnaires. Correlations between self-report and parent-report scores and between height gain and QoL improvements were assessed based on Pearson correlation coefficients. Results: Seventy-four children (42 boys, 32 girls), median age (± SD), 10.2 ± 3.0 years (range, 4.1 to 16.6 years), were included. The self-report PedsQL indicated significant improvements in emotional (P = 0.02) and social (P = 0.03) QoL. As assessed by the QoLiSSY, children reported improvement of social QoL (+0.2 SD; P = 0.04), and parents reported improvement of children's physical (+0.1 SD; P < 0.0001), emotional (+0.3 SD; P < 0.0001), and social (+0.3 SD; P < 0.0001) QoL. Height SD score (SDS) gains showed moderate positive correlations with QoLISSY self-report score gains (R = 0.53, R2 = 0.28; P < 0.001) and QoLISSY parent-report gains (R = 0.60, R2 = 0.41; P < 0.00001). Conclusions: After 1 year of GH treatment, children had significant gains in emotional and social QoL, as assessed by a general self-report questionnaire and height-specific parent-report questionnaire. (Copyright © 2019 Endocrine Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu